Literature DB >> 20951870

Influenza vaccines: the good, the bad, and the eggs.

Stacey Schultz-Cherry1, Jeremy C Jones.   

Abstract

Outbreaks of influenza A viruses continue to cause morbidity and mortality worldwide. The global disease burden of influenza is substantial. While antiviral therapies are available, influenza vaccines are the mainstay of efforts to reduce the substantial health burden from seasonal influenza. Inactivated influenza vaccines have been available since the 1940s, with live attenuated, cold-adapted vaccines becoming available in the United States in 2003. In spite of the successes, more research is needed to develop more effective seasonal influenza vaccines that provide long-lasting immunity and broad protection against strains that differ antigenically from vaccine viruses. This review introduces the virus and its disease, the current state of seasonal and pandemic influenza vaccines, and the challenges we face in the future.
Copyright © 2010 Elsevier Inc. All rights reserved.

Mesh:

Substances:

Year:  2010        PMID: 20951870     DOI: 10.1016/B978-0-12-385034-8.00003-X

Source DB:  PubMed          Journal:  Adv Virus Res        ISSN: 0065-3527            Impact factor:   9.937


  23 in total

1.  Virus aggregating peptide enhances the cell-mediated response to influenza virus vaccine.

Authors:  Jeremy C Jones; Erik W Settles; Curtis R Brandt; Stacey Schultz-Cherry
Journal:  Vaccine       Date:  2011-08-10       Impact factor: 3.641

2.  Compensatory hemagglutinin mutations alter antigenic properties of influenza viruses.

Authors:  Jaclyn L Myers; Katherine S Wetzel; Susanne L Linderman; Yang Li; Colleen B Sullivan; Scott E Hensley
Journal:  J Virol       Date:  2013-08-07       Impact factor: 5.103

3.  A novel bivalent vaccine based on a PB2-knockout influenza virus protects mice from pandemic H1N1 and highly pathogenic H5N1 virus challenges.

Authors:  Ryuta Uraki; Maki Kiso; Kiyoko Iwatsuki-Horimoto; Satoshi Fukuyama; Emi Takashita; Makoto Ozawa; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2013-05-08       Impact factor: 5.103

4.  Evaluation of multivalent H2 influenza pandemic vaccines in mice.

Authors:  Brian J Lenny; Stephanie Sonnberg; Angela F Danner; Kimberly Friedman; Richard J Webby; Robert G Webster; Jeremy C Jones
Journal:  Vaccine       Date:  2017-02-08       Impact factor: 3.641

5.  Influenza Hemagglutinin Head Domain Mimicry by Rational Design.

Authors:  V Vamsee Aditya Mallajosyula; Shiv Swaroop; Raghavan Varadarajan
Journal:  Protein J       Date:  2020-10-17       Impact factor: 2.371

6.  Trivalent inactivated influenza vaccines induce broad immunological reactivity to both internal virion components and influenza surface proteins.

Authors:  Katherine A Richards; Francisco A Chaves; Shabnam Alam; Andrea J Sant
Journal:  Vaccine       Date:  2012-10-22       Impact factor: 3.641

Review 7.  Challenges of selecting seasonal influenza vaccine strains for humans with diverse pre-exposure histories.

Authors:  Scott E Hensley
Journal:  Curr Opin Virol       Date:  2014-08-11       Impact factor: 7.090

8.  Identification of human vaccinees that possess antibodies targeting the egg-adapted hemagglutinin receptor binding site of an H1N1 influenza vaccine strain.

Authors:  Tyler A Garretson; Joshua G Petrie; Emily T Martin; Arnold S Monto; Scott E Hensley
Journal:  Vaccine       Date:  2018-05-31       Impact factor: 3.641

9.  Safety and immunogenicity of a plant-produced recombinant monomer hemagglutinin-based influenza vaccine derived from influenza A (H1N1)pdm09 virus: a Phase 1 dose-escalation study in healthy adults.

Authors:  James F Cummings; Melanie L Guerrero; James E Moon; Paige Waterman; Robin K Nielsen; Stacie Jefferson; F Liaini Gross; Kathy Hancock; Jacqueline M Katz; Vidadi Yusibov
Journal:  Vaccine       Date:  2013-10-12       Impact factor: 3.641

10.  Identification of Host Kinase Genes Required for Influenza Virus Replication and the Regulatory Role of MicroRNAs.

Authors:  Abhijeet Bakre; Lauren E Andersen; Victoria Meliopoulos; Keegan Coleman; Xiuzhen Yan; Paula Brooks; Jackelyn Crabtree; S Mark Tompkins; Ralph A Tripp
Journal:  PLoS One       Date:  2013-06-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.